Future studies including additional biomarkers (e.g. tau- and neuroinflammation-PET) may provide further insights into common and distinct aspects of the Alzheimer’s disease pathophysiological cascade in sporadic versus dominantly inherited disease. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.